CiplaCPLFY 94 3-Year ROIIC % is 9.21 as of Mar. 2026, which is 70% below its 10-year median of 30.68. GuruFocus rates CPLFY with a GF Score™ of 94/100. The stock has 6 warning signs investors should review. Among 944 Drug Manufacturers companies, Cipla ranks better than 58.79% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Cipla's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 9.21%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Cipla's 3-Year ROIIC % or its related term are showing as below:
CPLFY's 3-Year ROIIC % is ranked better than 58.79% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs CPLFY: 9.21
Cipla (OTCPK:CPLFY) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Cipla 3-Year ROIIC % Related Terms
Cipla 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Cipla's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Cipla's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Cipla (CPLFY) has a 3-Year ROIIC % of 9.21 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Cipla and its competitors. This is 70% below median its historical median of 30.68. According to the industry distribution chart, Cipla ranks #389 out of 944 companies in the Drug Manufacturers industry, placing it in the top 41.2%.
Is Cipla's 3-Year ROIIC % too high?
Cipla's current 3-Year ROIIC % of 9.21 is 70% below median its 10-year median of 30.68. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Cipla's value of 9.21 is 147.6% above this industry median. Based on the distribution chart, Cipla ranks #389 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cipla has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #389 out of 944 companies for 3-Year ROIIC %. This puts Cipla in the upper half of its industry. The industry median 3-Year ROIIC % is 3.72. Cipla's value of 9.21 is 147.6% above this benchmark. While the company's 10-year median is 30.68 vs. the industry median of 3.72, Cipla has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current 3-Year ROIIC % of 9.21 is 147.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current 3-Year ROIIC % is 9.21, which is 70% below median its own 10-year median of 30.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (CPLFY) has a current 3-Year ROIIC % of 9.21. The current 3-Year ROIIC % is 9.21, which is 70% below median its 10-year median of 30.68 and 147.6% above the Drug Manufacturers industry median of 3.72. Cipla's overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Cipla (CPLFY), the current 3-Year ROIIC % is 9.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPLFY has been successfully added to your 